Last reviewed · How we verify
AD504
AD504 is an oral small molecule that targets the orexin receptor to treat narcolepsy.
AD504 is an oral small molecule that targets the orexin receptor to treat narcolepsy. Used for Narcolepsy.
At a glance
| Generic name | AD504 |
|---|---|
| Sponsor | Apnimed |
| Drug class | Orexin receptor antagonist |
| Target | Orexin receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
AD504 works by selectively inhibiting the orexin receptor, which is involved in the regulation of sleep-wake cycles. This leads to increased wakefulness and reduced excessive daytime sleepiness in patients with narcolepsy.
Approved indications
- Narcolepsy
Common side effects
- Headache
- Nausea
- Dizziness
Key clinical trials
- Parallel Arm Trial of AD109 and AD504 In Patients With OSA (PHASE2)
- Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD504 CI brief — competitive landscape report
- AD504 updates RSS · CI watch RSS
- Apnimed portfolio CI